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Abstract
Background and objective Peripheral arterial disease (PAD)
is a common condition, in which atherosclerotic narrowing in
the arteries restricts blood supply to the leg muscles. In order
to support future model-based economic evaluations com-
paring methods of diagnosis in this area, a systematic review
of economic modelling studies was conducted.
Methods A systematic literature review was performed in
June 2017 to identify model-based economic evaluations of
diagnostic tests to detect PAD, with six individual databases
searched. The review was conducted in accordance with the
methods outlined in the Centre for Reviews and
Dissemination’s guidance for undertaking reviews in health-
care, and appropriate inclusion criteria were applied. Relevant
data were extracted, and studies were quality assessed.
Results Seven studies were included in the final review, all
of which were published between 1995 and 2014. There
was wide variation in the types of diagnostic test com-
pared. The majority of the studies (six of seven) referenced
the sources used to develop their model, and all studies
stated and justified the structural assumptions. Reporting of
the data within the included studies could have been
improved. Only one identified study focused on the cost-
effectiveness of a test typically used in primary care.
Conclusions This review brings together all applied mod-
elling methods for tests used in the diagnosis of PAD,
which could be used to support future model-based eco-
nomic evaluations in this field. The limited modelling work
available on tests typically used for the detection of PAD in
primary care, in particular, highlights the importance of
future work in this area.
Key Points for Decision Makers
This review summarises the methodologies and
results of all model-based economic evaluations
focussing on tests used in the diagnosis of PAD.
The review highlights the limited amount of model-
based economic evaluation literature available in this
clinical area, in particular for tests used in a primary
care setting.
Methods and findings highlighted in this review may
be used to support future modelling work in related
areas.
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1 Introduction
Peripheral arterial disease (PAD) is a common condition in
which atherosclerotic narrowing, or occlusion, in the
arteries restricts blood supply to the leg muscles [1]. PAD
can cause leg pain on walking (intermittent claudication)
and, in more severe cases, may cause ulcers or gangrene
and could potentially lead to amputation. The prevalence of
PAD in the UK ranges from 3 to 10%, rising to 15–20% in
the elderly [2]. One in five people aged 65–75 years in the
UK have clinical evidence of PAD, although only a quarter
of them are symptomatic [3]. Due to underlying
atherosclerosis, patients with PAD tend to have reduced
functional capacity [4, 5] and an increased risk of cardio-
vascular morbidity, i.e. myocardial infarction and stroke,
and mortality [6–8].
Detecting PAD early gives the opportunity to try and
control its associated vascular risk factors, reduce adverse
cardiovascular events and avoid the need for surgery. The
National Institute for Health and Care Excellence (NICE)
clinical guidelines for PAD (CG147) [9] recommend
diagnosis through symptoms and signs and measurement of
the ankle brachial pressure index (ABPI) in primary care.
In a secondary care setting, diagnosis is often made through
imaging techniques such as magnetic resonance angiogra-
phy (MRA), digital subtraction angiography (DSA) and
duplex ultrasound (DUS), amongst others.
As part of a wider study exploring the costs and effects
of introducing a new test for the diagnosis of PAD, a
systematic review of existing economic evidence in the
area was required. Although information on the relative
costs and effects of alternative methods to detect PAD are
sparse, a limited number of economic decision modelling
analyses have been conducted in this area. The aim of this
review was to provide a summary of existing model-based
economic evaluation literature, up until the year 2017, on
currently available methods to detect PAD in either a pri-
mary or secondary care setting in order to support future
model-based economic evaluations comparing methods of
diagnosis in this clinical area.
The specific objectives of this review were to:
1. map the relevant economic evidence base for model-
based economic evaluations of methods to detect PAD
in both primary and secondary care;
2. assess the methodological quality of the identified
studies;
3. identify key strengths and weaknesses of the identified
studies when comparing the different diagnostic tests;
and
4. highlight the cost-effectiveness evidence on existing
methods of diagnosis.
2 Methods
A systematic literature review was conducted to identify
model-based economic evaluations of diagnostic tests to
detect PAD in either a primary or secondary care setting.
The review work was conducted in accordance with the
methods outlined in the Centre for Reviews and Dissemi-
nation’s guidance for undertaking reviews in healthcare,
which provides a comprehensive guide to best practice in
conducting reviews in healthcare [10]. Studies (individual
papers) were required to meet each of the following criteria
in order to be included in the review:
• population were adults ([ 18 years) with suspected
PAD or at risk of PAD, adults with intermittent
claudication or adults with PAD undergoing further
diagnostic testing;
• included an intervention targeted at the detection of
PAD (in primary or secondary care); and
• involved a full model-based economic evaluation
(study in which a comparison of two or more
interventions or care alternatives is undertaken, and in
which both the costs and outcomes of the alternatives
are examined).
There were no restrictions on the type of comparator or
the outcomes that needed to be included in the study. There
were no restrictions placed on the publication year. Con-
ference abstracts were excluded due to concerns about
quality, and the potential for there to be insufficient detail
reported. Studies were excluded if they were not in the
English language or if they did not meet the inclusion
criteria described.
2.1 Search Strategy
Systematic searches were undertaken in the following
databases:
• UK National Health Service (NHS) Economic Evalu-
ation Database (EED).
• MEDLINE.
• Cochrane Central.
• Database of Reviews of Effectiveness (DARE).
• Cochrane Database of Systematic Reviews.
• Health Technology Assessment (HTA) database.
The searches were undertaken by an information spe-
cialist (SR) with experience in devising search strategies
for economic evaluations. Searches were iterative to take
into account any terms, phrases or concepts that were
discovered during other parts of the review. These searches
were undertaken in June 2017. Records were downloaded
from databases and then imported into EndNote X7
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(Thomas Reuters, Toronto, ONT, Canada) bibliographic
software, where duplicate records were removed and
remaining recorded were screened. The complete search
strategy, designed to run in MEDLINE (OVID), is outlined
in Electronic Supplementary Material (Appendix 1).
2.2 Study Selection
The searches identified 419 publications. Two systematic
reviewers (JO’C and EM) independently screened the titles
and abstracts to identify potentially relevant studies. Dis-
agreements were resolved by a third reviewer (DC). Four
papers were excluded on the basis of being a duplicate
study and 409 studies were excluded as they did not
meet all of the inclusion criteria applied, or they were
either a conference abstract and/or were not in the English
language. Six studies were deemed adequate to be poten-
tially included in the review following title and abstract
screening, and the full text of each of these papers was
examined. Once again, the two reviewers independently
screened the full publications and five of the six studies
were considered appropriate for inclusion in the review.
The sixth study was excluded as it did not meet all of the
inclusion criteria. The references of these five studies were
hand-searched and two additional potentially relevant
studies were identified. When independently checked by
the two reviewers, these papers were deemed to meet the
inclusion criteria for the review. Therefore, seven studies
were included in the final review. The flow chart of the
selection process is depicted in Fig. 1.
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2.3 Data Extraction
Relevant data from included studies were extracted
accordingly. Data extracted from each study included the
setting and patient population, the perspective of the study
and the type of economic evaluation conducted. Addi-
tionally, the type of model structure, the comparators
included in the analysis, and the time cycle and time
horizon of the models were identified and extracted for
each study.
2.4 Quality Assessment
Following data extraction, a quality assessment of the
included studies was undertaken using the Philips
checklist, a quality assessment tool developed for deci-
sion-analytic modelling studies [11]. In this tool, studies
are assessed under the three general components of a
model—‘structure’, ‘data’ and ‘consistency’—and results
of the quality assessment are presented under these
headings. The full list of questions included in the
checklist is presented in Table 3 in Electronic Supple-
mentary Material (Appendix 2). The quality assessment
was used to assess the methodological quality of the
included studies.
3 Results
Seven studies were included in the review. All studies
identified for this review were published between 1995 and
2014, with no published studies identified from before or
after these dates. An overview of the included studies is
first presented, followed by a description of the data
extracted from each study. Next, an assessment of the
methodological quality of included studies, and a descrip-
tion of their shortcomings, is presented. Finally, the cost-
effectiveness evidence on existing methods of diagnosis is
presented. A brief overview of the included studies is
presented in Sect. 3.1, with a full overview presented in
Table 1.
3.1 Overview of Included Studies
Vaidya et al. [12] evaluated the lifetime cost-effective-
ness of the strategy of selective PAD screening with
ABPI and consequent preventive treatment compared
with no screening and no preventive treatment.
Coffi et al. [13] compared duplex scanning in combina-
tion with arterial DSA with two other diagnostic
strategies: duplex scanning plus supplementary angiog-
raphy if duplex scanning is inconclusive, and duplex
scanning plus confirmative angiography if duplex scan-
ning is either inconclusive or shows lesions.
Visser et al. [14] compared the cost-effectiveness of
gadolinium-enhanced MRA, colour-guided DUS and
intra-arterial DSA used in a variety of diagnostic
strategies.
Visser et al. [15] compared the cost-effectiveness of
multi-detector row computed tomography angiography
(CTA) with that of gadolinium-enhanced MRA.
Collins et al. [16] compared the cost-effectiveness of
DUS, MRA and CTA for the diagnosis and assessment
of symptomatic lower-limb PAD.
Yin et al. [17] compared the cost-effectiveness of MRA
with conventional angiography.
Visser et al. [18] compared the cost-effectiveness of
MRA, duplex ultrasonography and DSA.
3.2 Data Extraction
3.2.1 Setting and Patient Population
Four studies were performed in the Netherlands [12–15],
one study in the UK [16] and two studies in the USA
[17, 18]. The patient population in four studies
[12, 13, 16, 17] was patients with PAD, or suspected PAD.
One of these studies [12] specifically looked at patients
with suspected PAD at high risk of experiencing acute
cardiovascular events (asymptomatic patients over the age
of 55 years), and another [17] looked at patients with
suspected PAD which was limb-threatening (comparison of
interventions for pre-operative evaluation). Another con-
centrated on patients with PAD [13], while the other
focused on patients either with intermittent claudication or
with limb-threatening ischaemia, who needed to undergo
lower-limb vascular imaging to formulate an appropriate
treatment plan for their condition [16]. The patient popu-
lation in the remaining three studies [14, 15, 18] was
patients with intermittent claudication, with one of these
studies [18] specifically looking at patients with lifestyle-
limiting intermittent claudication. Patients in these three
studies [14, 15, 18] were at a stage where they would
require a diagnostic test as part of pre-treatment imaging
work-up.
3.2.2 Perspective
The majority of the studies (five of seven) were conducted
from a societal perspective [12, 14, 15, 17, 18]. One study
[13] was conducted from a provider (hospital) perspective,
and another [16] was conducted from a UK NHS
perspective.
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3.2.3 Type of Economic Evaluation
Two studies performed both a cost-effectiveness analysis
(CEA) and a cost-utility analysis (CUA) [12, 16]. One
study performed a CEA only [13], and four studies per-
formed a CUA only [14, 15, 17, 18]. One study [15]
additionally undertook a threshold analysis. Of the studies
that conducted a CEA, one study [12] used life-years
gained as an outcome measure, one study [13] used an
additional correctly identified case and one study [16] used
a correctly diagnosed patient as the outcome measure. All
of the studies that conducted a CUA [12, 14–18] used
quality-adjusted life-years (QALYs) gained as the outcome
measure.
3.2.4 Model Structure and Comparators
Four studies [12, 15, 16, 18] were model-based economic
evaluations involving a decision tree combined with a
Markov state transition model. Of these, one study [12]
evaluated a screening strategy using the ABPI; one study
[15] evaluated multi-detector row CTA, as compared with
gadolinium-enhanced MRA; one study [16] compared
contrast angiography with MRA, DUS and CTA; and one
Table 1 Overview of included studies
Study Year Location Population Perspective Type of
economic
evaluation
Type of decision
model
Intervention(s) assessed
Vaidya
et al.
[12]
2014 Netherlands High risk of PAD
(high risk of
experiencing
acute
cardiovascular
events)
Societal CEA and
CUA
Decision tree
combined with a
Markov state
transition model
Screening strategy using the ABPI
Coffi
et al.
[13]
2008 Netherlands PAD Provider
(hospital)
CEA Decision tree Comparison of duplex scanning in
combination with arterial DSA, with
two other diagnostic strategies:
duplex scanning plus supplementary
angiography if duplex scanning is
inconclusive, and duplex scanning
plus confirmative angiography if
duplex scanning is either
inconclusive or shows lesions
Visser
et al.
[14]
2003 Netherlands Intermittent
claudication
Societal CUA Markov Monte
Carlo model
embedded in a
large decision-
analytic model
Comparison of gadolinium-enhanced
MRA, colour-guided duplex
ultrasound and intra-arterial DSA
used in a variety of diagnostic
strategies
Visser
et al.
[15]
2003 Netherlands Intermittent
claudication
Societal CUA and
threshold
analysis
Decision tree
combined with a
Markov state
transition model
Multi-detector row CT angiography
compared with gadolinium-
enhanced MRA
Collins
et al.
[16]
2007 UK Intermittent
claudication or
limb-threatening
ischaemia
NHS CEA and
CUA
Decision tree
combined with a
Markov state
transition model
Comparison of contrast angiography
with MRA, DUS and CT
angiography
Yin
et al.
[17]
1995 USA PAD (limb-
threatening PAD)
Societal CUA Decision tree Comparison of MRA with
conventional angiography
Visser
et al.
[18]
2003 USA Intermittent
claudication
(lifestyle-limiting
intermittent
claudication)
Societal CUA Decision tree
combined with a
Markov state
transition model
Pre-treatment work-up using MRA,
DUS or intra-arterial DSA
APBI ankle brachial pressure index, CEA cost-effectiveness analysis, CUA cost-utility analysis, CT computed tomography, DSA digital sub-
traction angiography, DUS duplex ultrasound, MRA magnetic resonance angiography, NHS UK National Health Service, PAD peripheral arterial
disease
Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral… 25
study [18] evaluated pre-treatment work-up using MRA,
DUS or intra-arterial DSA.
Two studies [13, 17] were model-based economic
evaluations involving a decision tree only. Of these, one
study [13] compared duplex scanning in combination with
arterial DSA with two other diagnostic strategies (duplex
scanning plus supplementary angiography if duplex scan-
ning is inconclusive, and duplex scanning plus confirma-
tive angiography if duplex scanning is either inconclusive
or shows lesions). The other study [17] compared MRA
with conventional angiography.
One study [14] was a model-based economic evaluation
involving a Markov Monte Carlo model embedded in a
large decision-analytic model. This study compared
gadolinium-enhanced MRA, colour-guided DUS and intra-
arterial DSA used in a variety of diagnostic strategies.
3.2.5 Time Horizon and Time Cycle
Four studies used a 1-year time cycle and lifetime time
horizon [12, 14, 15, 18]. Although three of these did not
explicitly state the time cycle used [14, 15, 18], it did
appear to be 1 year based on the parameters included in the
model. One study included a short-term model with a
1-year time horizon, and a long-term model with a lifetime
time horizon, the latter of which used a 1-year time cycle
[16]. For two studies, time cycle and time horizon were not
relevant as the model structure was a decision tree [13, 17].
3.3 Methodological Quality of the Included Studies
The results of the quality assessments are presented in
Table 3 in Electronic Supplementary Material (Appendix
2), with a description of the findings presented below.
Results are discussed under the headings provided in the
framework used (structure, data and consistency) [11].
3.3.1 Structure
General All studies clearly stated a decision problem, and
the specified objectives of all models were consistent with
these stated decision problems. None of the included
studies clearly specified the primary decision maker,
although it did always appear to be the healthcare provider.
All of the included studies stated and justified the scope of
their models. The outcomes of the models of the included
papers were all consistent with the overall objectives of the
model. For all studies, the model’s inputs were consistent
with the chosen perspective.
Model Structure Four of the included studies’ models
were based on previously published models [14–16, 18]
and two others stated that the model structure was based on
reviewing the published literature [12, 13]. The final study
[17] used a de novo decision-analytic model in their
analysis. Of the studies that used previous literature to
inform their model structure, all but one [13] clearly ref-
erenced the sources used to develop their models so it
would be possible for the reader to refer to that published
literature to assess the quality and appropriateness of the
models included. For all studies, the structure of the model
was consistent with a coherent theory of the health con-
dition under evaluation. All of the included studies clearly
stated the structural assumptions used in their models and
these were appropriately justified. For all studies, these
structural assumptions were reasonable and consistent with
the stated scope and perspective, where stated.
Comparators All of the included studies provided a
clear description of the options under evaluation in their
models. For only one study could it be said that all feasible
and practical options were not evaluated [16]. This study
provided a justification for this exclusion, which was cor-
roborated by expert opinion and, therefore, can be con-
sidered appropriate.
Model Type and Time Horizon The model types chosen
by the included studies were all appropriate. Five studies
[12, 14–16, 18] had sufficiently lengthy time horizons
(lifetime) to assess the long-term differences (in terms of
costs and effects) between the options. All of these studies
used 1-year time cycles. For two studies, time cycle and
time horizon were not relevant as the model structure was a
decision tree [13, 17]. The duration of treatment and
duration of treatment effect was described and justified in
all relevant studies.
Face Validity of Structure For the majority of the studies
[12–17], the disease states/pathways used in their models
reflect the underlying biological process of the condition.
For one study [18], the initial decision tree is appropriate;
however, the longer-term Markov model was not well-de-
scribed and so its appropriateness is unclear. For the studies
where cycle length was applicable [12, 14–16, 18], the
cycle length was explicitly stated in only two cases
[12, 16].
3.3.2 Data
Data Identification For all studies, the identification of data
was reasonably well-reported. Five studies did not discuss
alternative sources of data [12–15, 18], nor the rea-
son(s) for selecting the included data over alternative data.
From the remaining studies, one study [17] described and
justified the choices made between data sources, and one
study [16] used pooled estimates of the identified studies.
Five studies justified the process of selecting key parame-
ters and used systematic methods to identify the data
required for the model [12, 14–17]. Only two studies dis-
cussed quality assessment of the included data [16, 17].
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Two studies [14, 16] discussed the use of expert opinion to
populate their model. Of these, only one [16] described and
justified the expert opinion used.
Data Analysis Only three studies [14–16] provided a
justification for the choice of baseline data used. Four
studies [12, 14–16] appropriately described the calculation
of the transition probabilities used. None of the studies
discussed the application of a half-cycle correction to costs
and outcomes. None of the studies derived relative treat-
ment effects using trial data. Five of the studies required an
extrapolation of results to final outcomes
[12, 14, 15, 17, 18]. Of these, two studies described these
extrapolations [12, 17] and one study justified the methods
used and used alternative extrapolation assumptions in the
sensitivity analysis [17]. The other three studies
[14, 15, 18] did not go into detail about the extrapolation of
results.
Utilities Six studies conducted a CUA [12, 14–18],
either on its own or alongside another form of analysis, and
all six of these studies clearly referenced the source of the
utility weights used in their studies (five used EQ-5D
scores [12, 14–16, 18], while one used the Quality of Well-
Being Scale [17]). Only one study [15] provided a justifi-
cation of the methods of derivation used to derive the
utility weights used; the remaining studies did not discuss
methods of derivation and only referenced the sources of
the data used. The utilities incorporated in the models were
appropriate for the majority of these studies [14–16, 18];
however, one study did not provide sufficient detail [12],
while another study used a number of assumptions to
derive utility values [17].
Costs One study used published literature to identify
relevant health state costs [12], but systematic methods to
identify this literature were not reported. Additional treat-
ment, travel and productivity loss costs were sourced from
routine sources available in the country where the study
was conducted, and all can be considered appropriate. One
study carried out a micro-costing exercise (focusing on
personnel, material and overheads) [13] to estimate the
costs associated with alternative diagnostic strategies. All
relevant costs were included in the analysis, and all were
identified using appropriate sources of data. One study
followed the Dutch guidelines for cost calculations in
healthcare [14] and included direct medical costs (person-
nel, materials, housing, equipment, hospital admissions and
overheads) and direct non-medical costs to the patient,
including travel expenses and patient time. All costs
included were identified using appropriate sources. These
same cost categories were presented in another study [18],
but from a US perspective, with appropriate data included
and suitable identification methods applied. One study used
a combination of data from Medicare reimbursement rates
and data identified in the literature to include in the
economic model [15]. The process of identifying cost data
from the literature in this study was not well-reported. One
study sourced the cost of the test, and patient management,
from the literature, with additional medication costs iden-
tified using routine data sources [16]. One study focused on
the costs to the hospital in carrying out the test, and as a
result of subsequent patient management, and additional
productivity loss costs due to the hospitalisation of the
patient [17]. All studies included appropriate cost data
given the perspective of the analysis.
Data Referencing All of the seven included papers ref-
erenced the data incorporated in their respective studies.
The process of data incorporation was transparently pre-
sented in four studies [12, 14, 16, 17]. One study provided
limited details of data incorporation [13] and two studies
did not discuss data incorporation [15, 18].
Uncertainty None of the seven included papers addres-
sed all four principal types of uncertainty: methodological
uncertainty, structural uncertainty, parameter uncertainty
and patient population-related uncertainty (i.e. uncertainty
related to potential patient heterogeneity). Only one study
[16] provided any justification for this omission. Only two
studies [13, 14] addressed methodological uncertainties in
their models. Four studies [13, 15, 16, 18] made efforts to
address the structural uncertainties within their models.
None of the included studies discussed the issue of
heterogeneity in their studies. For all studies, the method of
assessing parameter uncertainty was appropriate.
3.3.3 Consistency
None of the included studies discussed whether the math-
ematical logic of their models was tested and, so, it is not
clear if this task was undertaken. However, the conclusions
provided by each of the included studies can be considered
valid given the data presented. None of the studies reported
counterintuitive results. Four studies [12, 13, 16, 18] dis-
cussed the results of previous models and discussed their
results in relation to these previous studies. One study [14]
discussed another study broadly by comparing the US with
the Danish results; as such, this discussion was more on the
generalisability of the results across these two countries
rather than a calibration of the study’s results. The two
remaining studies [15, 17] discussed previous studies but a
comparison of results was not formally conducted or
presented.
3.4 Cost-Effectiveness Results
An overview of the base-case cost-effectiveness findings
from each of the included studies is presented in Table 2.
Of the seven studies included in the final review, only one
of these [12] assessed the cost-effectiveness of an
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Table 2 Summary of base-case cost-effectiveness results from included studies
Study Interventions being compared Cost-effectiveness results
Vaidya
et al.
[12]
Targeted ABI screening and treatment
with low dose aspirin
Targeted ABI screening and treatment with low-dose aspirin was a dominant strategy
(cheaper and produced more QALYs)
‘‘No screening and no preventive
treatment’’
Coffi et al.
[13]
Duplex scanning plus confirmative
angiography
Duplex scanning plus confirmative angiography was dominated by duplex scanning plus
supplementary angiography
Duplex scanning plus supplementary
angiography
The ICER for arterial DSA when compared with duplex scanning plus supplementary
angiography was €8443, i.e. €8443 per additional correctly identified case
Arterial DSA
Visser
et al.
[14]
The conservative strategy The conservative strategy was the least effective and least costly (6.0606 QALYs and
€6793)
MRA ? PTA/EX MRA ? PTA/EX was more effective and more costly (6.1487 QALYs and €8566) than
the conservative strategy
All other management strategies were inferior by extended dominance (ICER greater than
that of a more effective intervention)
Strategy DSA ? PTA/BS/EX Strategy DSA ? PTA/BS/EX was the most effective strategy but was also more
expensive (6.2254 QALYs and €18,583) than MRA ? PTA/EX
Visser
et al.
[15]
MRA In the minimally invasive treatment scenario, MRA yielded 6.1487 QALYs at a cost of
US$21,942
A new imaging modality At a societal willingness to pay of $100,000 per QALY, a new imaging modality was
equivalent to MRA in terms of cost-effectiveness if the cost of the modality was
US$420, the sensitivity for detection of significant stenosis was 90%, and 20% of the
patients required additional work-up owing to equivocal CTA results
With these conditions and with the assumption of a threshold ICER of US$100,000 per
QALY, the strategy with the new imaging modality yielded 6.1490 QALYs at a cost of
US$21,965
Collins
et al.
[16]
Duplex 2D TOF MRA For the short-term model, the most cost-effective imaging modality appeared to be duplex
ultrasound, which presented a cost of £2617 per CDPwATP and an incremental cost per
additional CDPwATP obtained, compared with 2D TOF MRA, equal to £2260
Duplex ultrasound 1 year after initial treatment, duplex ultrasound remained the dominant strategy, incurring
a cost per QALY of £13,646
When analysis of stenosis is limited to a section of the leg, either above the knee or below
the knee, 2D TOF MRA appears to be the most cost-effective preoperative diagnostic
strategy
Yin et al.
[17]
MRA Total discounted QALYs gained per patient if MRA replaces conventional
angiography = 0.0085
Incremental cost of treatment for an average patient = US$220
Conventional angiography
ICER = US$25,895
Visser
et al.
[18]
No diagnostic work-up No diagnostic work-up yielded the lowest effectiveness and costs
MRA The ICER for MRA was US$35,000/QALY compared with no diagnostic work-up
DSA The ICER for DSA was US$471,000/QALY compared with MRA
Duplex ultrasound Duplex ultrasound was less effective and more costly than MRA; however, the differences
in QALYs and costs were marginal
Under the more invasive treatment scenario, DSA was the most effective strategy, with an
ICER of US$179,000/QALY compared with no diagnostic work-up
MRA and duplex ultrasound were both dominated by DSA
2D two-dimensional, ABI ankle brachial index, CDPwATP correctly diagnosed patient with accurate treatment plan, CTA computed tomography
angiography, DSA digital subtraction angiography, DSA ? PTA/BS/EX digital subtraction angiography ? percutaneous transluminal angioplasty
with selective stent placement/bypass surgery/supervised exercise, ICER incremental cost-effectiveness ratio, MRA magnetic resonance
angiography, MRA ? PTA/EX magnetic resonance angiography ? percutaneous transluminal angioplasty with supervised exercise, QALY
quality-adjusted life-year, TOF time of flight
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intervention typically used in a primary care setting for the
diagnosis of PAD: ABPI. The remaining six studies
[13–18] focused on the cost-effectiveness of imaging
techniques that would typically be conducted in secondary
care. The study which explored the potential cost-effec-
tiveness of ABPI [12] found that the intervention of
‘‘screening with ABPI and providing treatment to test
positive patients’’ was dominant (cheaper and more effec-
tive) than the comparator of ‘‘no testing and no preventive
treatment’’. From the results of the other six studies
[13–18], there was no one definitive cost-effective method
of diagnosis as there was wide variation in the types of
intervention assessed, as well as the combination of tests
and techniques included in the individual analyses.
4 Discussion
A systematic review of the literature, up until the year
2017, to identify model-based economic evaluations com-
paring techniques for detecting PAD, was conducted.
Seven studies were included in the full review, all of which
were published between 1995 and 2014.
The population included in the analyses was variable,
with two studies focusing on patients with suspected PAD
[12, 17], one study focusing on patients with clearly
defined PAD [13], one study focusing on patients with
intermittent claudication or limb-threatening ischaemia
[16] and three studies focusing on patients with intermittent
claudication [14, 15, 18]. Notably, four of the studies were
performed in the Netherlands [12–15]; however, two of
these studies were conducted by the same lead author and
were based on a similar analysis [14, 15]. The most com-
mon type of model structure used amongst included studies
was a Markov state transition model embedded in a larger
decision-analytic model, which was used in the three
studies published by Visser et al. [14, 15, 18], and in the
studies by Vaidya et al. [12] and Collins et al. [16].
In terms of the model structure in included studies, these
were of adequate quality, with the majority of the included
studies reporting and justifying the relevant information
associated with model structure. However, of the included
studies that used previously published models in their
analyses, the methods used to develop these model struc-
tures were not well-reported and readers would need to
refer to the references provided to assess their quality and
appropriateness.
The reporting of the data within the included studies
could have been improved. Only one study [16] described
the use of systematic methods to identify the data required
for the model, and described a quality assessment of the
data used. Only three studies [14–16] provided a justifi-
cation for the choice of baseline data used. All of the seven
included studies referenced the data incorporated in their
studies. The process of data incorporation was transpar-
ently presented in four studies [12, 14, 16, 17]. One study
provided limited details of data incorporation [13] and two
studies did not discuss data incorporation [15, 18]. Finally,
none of the seven studies addressed all four principal types
of uncertainty, with only one study [16] providing any
justification for this omission.
The conclusions provided in each of the included studies
may be considered valid given the data presented in the
studies. The majority of studies drew comparisons between
their own findings and previous research, and the studies
that did not make a formal comparison still placed their
results in the context of existing evidence.
The cost-effectiveness findings from each of the studies
are not presented with the intention of outlining a defini-
tively cost-effective technique for the detection of PAD.
The interventions described in many of the studies are
paired with a variety of complimentary tests/treatments and
the results can only be considered relevant in light of the
context in which they are presented. However, it is worth
noting that only one of the included studies [12] involved
an evaluation of a test typically used for the diagnosis of
PAD in a primary care setting: ABPI. All other studies
evaluated tests which are more commonly utilised in sec-
ondary care, such as imaging techniques.
A limitation of the review is that the number of studies
identified is quite low, and this sample may not be con-
sidered robust enough to make any definitive conclusions
about the quality of reporting of modelling studies in this
clinical area. This was partially due to the focus on model-
based studies specifically, with all other economic evalu-
ations excluded from the review.
This systematic review shows the limited amount of
model-based economic evaluation literature that currently
exists in this clinical area and the scope that exists for
future work. In particular, there is a lack of related work
involving tests that would generally be used in primary
care and there is scope for future work to focus on the costs
and health outcomes of such tests. Additionally, any future
reviews in this area may choose to include all economic
evaluations, rather than focusing on modelling studies
specifically, to determine how much more data would be
available if this exclusion criterion was not applied.
5 Conclusion
This review brings together all applied modelling methods
for tests used in the diagnosis of PAD, the results of which
could be used to inform future model-based economic
evaluations in this field. The limited cost-effectiveness
information available on tests typically used for the
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detection of PAD in a primary care setting, in particular,
highlights the importance of future work in this area.
Acknowledgements Eoin Moloney gratefully acknowledges the
work carried out on the funded study by all co-authors of this paper
and all individuals involved in the ‘Notepad’ study. The views and
opinions expressed by authors in this publication are those of the
authors and do not necessarily reflect those of the NHS, the National
Institute for Health Research or the Department of Health.
Author Contributions Shannon Robalino was responsible for per-
forming the search for relevant studies. Joanne O’Connor and Eoin
Moloney were responsible for deciding on the studies that would be
included in the final review, extracting relevant data and performing
the quality assessment of included studies. All other co-authors pro-
vided input on the final submitted version of the paper.
Compliance with Ethical Standards
Funding This report is independent research funded by the National
Institute for Health Research (Invention for Innovation, ‘‘Innovative
photoplethysmography technology for rapid non-invasive assessment
of peripheral arterial disease in primary care’’, II-C1-0412-20003).
The views expressed in this publication are those of the author(s) and
not necessarily those of the UK National Health Service (NHS), the
National Institute for Health Research or the Department of Health.
This paper is based on the systematic review work carried out as part
of the main ‘Notepad’ study. This study involved the development
and evaluation of the PulsePad diagnostic medical device, a test for
the diagnosis of Peripheral Arterial Disease in primary care.
Conflict of interest Relationships with entities that have a financial
interest in the subject matter of the article have been clearly stated in
the Conflict of Interest Disclosure Statements provided by Andrew
Sims and John Allen. These relationships relate to their employment
by the Newcastle upon Tyne Hospitals (NUTH) NHS Foundation
Trust, which received grant income from the National Institute for
Health Research to develop the diagnostic device outlined previously.
Authors Eoin Moloney, Joanne O’Connor, Dawn Craig, Shannon
Robalino, Alexandros Chrysos, Mehdi Javanbakht, Gerard Stansby
and Scott Wilkes have no conflicts of interest to report.
Data availability statement The authors declare that all of the data
supporting the findings of this study are available within the article (or
the Appendices of the article).
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. NHS Choices. Peripheral arterial disease (PAD). 2014. https://
www.nhs.uk/conditions/peripheral-arterial-disease-pad/. Acces-
sed 15 Sep 2016.
2. Burns P, Gough S, Bradbury AW, et al. Management of
peripheral arterial disease in primary care. BMJ.
2003;326(7389):584–8.
3. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history
and cardiovascular events in symptomatic and asymptomatic
peripheral arterial disease in the general population. Int J Epi-
demiol. 1996;25(6):1172–81.
4. McDermott MM, Liu K, Greenland P, et al. Functional decline in
peripheral arterial disease: associations with the ankle brachial
index and leg symptoms. JAMA. 2004;292:453–61.
5. McDermott MM, Guralnik JM, Tian L, et al. Associations of
borderline and low normal ankle-brachial index values with
functional decline at 5-year follow-up: the WALCS (Walking and
Leg Circulation Study). J Am Coll Cardiol. 2009;53:1056–62.
6. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index
combined with Framingham Risk Score to predict cardiovascular
events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
7. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular
event rates in outpatients with atherothrombosis. JAMA.
2007;297:1197–206.
8. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease:
morbidity and mortality implications. Circulation.
2006;114:688–99.
9. National Institute for Health and Care Excellence. Lower limb
peripheral arterial disease costing report - implementing NICE
guidance. NICE Clinical Guideline 147. London: NICE; 2012.
10. Centre for Reviews and Dissemination. Systematic Reviews:
CRD’s guidance for undertaking reviews in health care. York:
University of York; 2009.
11. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines
for decision-analytic modelling in health technology assessment:
a review and consolidation of quality assessment. Pharma-
coeconomics. 2006;24(4):355–71.
12. Vaidya A, Joore MA, Ten Cate-Hoek AJ, et al. Screen or not to
screen for peripheral arterial disease: guidance from a decision
model. BMC Public Health. 2014;14:89.
13. Coffi SB, Ubbink DT, Dijkgraaf MG, et al. Cost-effectiveness of
identifying aortoiliac and femoropopliteal arterial disease with
angiography or duplex scanning. Eur J Radiol. 2008;66(1):142–8.
14. Visser K, de Vries SO, Kitslaar PJ, et al. Cost-effectiveness of
diagnostic imaging work-up and treatment for patients with
intermittent claudication in the Netherlands. Eur J Vasc Endovasc
Surg. 2003;25:213–23.
15. Visser K, Kock MC, Kuntz KM, et al. Cost-effectiveness targets
for multi–detector row CT angiography in the work-up of patients
with intermittent claudication. Radiology. 2003;227(3):647–56.
16. Collins R, Cranny G, Burch J, et al. A systematic review of
duplex ultrasound, magnetic resonance angiography and com-
puted tomography angiography for the diagnosis and assessment
of symptomatic, lower limb peripheral arterial disease. Health
Technol Assess. 2007;11(20):3–5.
17. Yin D, Baum RA, Carpenter JP, et al. Cost-effectiveness of MR
angiography in cases of limb-threatening peripheral vascular
disease. Radiology. 1995;194(3):757–64.
18. Visser K, Kuntz KM, Donaldson MC, et al. Pretreatment imaging
workup for patients with intermittent claudication: a cost-effec-
tiveness analysis. J Vasc Interv Radiol. 2003;14(1):53–62.
30 E. Moloney et al.
